A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113
详细信息 查看全文
- 作者：Rachel E. Sanborn ; Jyoti D. Patel ; Gregory A. Masters ; Nagesh Jayaram ; Anthony Stephens ; Michael Guarino ; Jamal Misleh ; Jingwei Wu and Nasser Hanna
- 刊名：Cancer
- 出版年：2017
- 出版时间：January 15, 2017
- 年：2017
- 卷：123
- 期：2
- 页码：303-311
- 全文大小：236K
- ISSN：1097-0142
文摘
This randomized, double-blind, phase 2 trial evaluated whether the addition of vandetanib to platinum plus etoposide for previously untreated extensive-stage small cell lung cancer (SCLC) prolonged the time to disease progression in comparison with chemotherapy alone.